PolyPid Ltd
NASDAQ:PYPD
PolyPid Ltd
Net Income (Common)
PolyPid Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
PolyPid Ltd
NASDAQ:PYPD
|
Net Income (Common)
-$23.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Net Income (Common)
-$559m
|
CAGR 3-Years
48%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Net Income (Common)
$45.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-18%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Net Income (Common)
₪20.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
Mediwound Ltd
NASDAQ:MDWD
|
Net Income (Common)
-$6.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
8%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Net Income (Common)
-₪8.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-62%
|
CAGR 10-Years
N/A
|
See Also
What is PolyPid Ltd's Net Income (Common)?
Net Income (Common)
-23.9m
USD
Based on the financial report for Dec 31, 2023, PolyPid Ltd's Net Income (Common) amounts to -23.9m USD.
What is PolyPid Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
15%
Over the last year, the Net Income (Common) growth was 40%. The average annual Net Income (Common) growth rates for PolyPid Ltd have been 15% over the past three years .